The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment
[Display omitted] •Gut microbiota impacts tumor response to immune checkpoint inhibitors (ICI).•The potential role of the gut wall regarding the tumor response to ICI has received little attention.•Selective markers can define gut wall integrity and the intestinal immune system.•Clinical interventio...
Saved in:
| Published in | Cancer treatment reviews Vol. 107; p. 102406 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
01.06.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | [Display omitted]
•Gut microbiota impacts tumor response to immune checkpoint inhibitors (ICI).•The potential role of the gut wall regarding the tumor response to ICI has received little attention.•Selective markers can define gut wall integrity and the intestinal immune system.•Clinical interventions are available that modify key components of the gut wall.•The gut wall’s potential to improve ICI efficacy should be further explored.
The gut wall is the largest immune organ and forms a barrier through which gut microbiota interact with the immune system in the rest of the body. Gut microbiota composition plays a role in the strength and timing of the anticancer immune response on immune checkpoint inhibitors (ICI). Surprisingly, the effects of gut wall characteristics, such as physical barrier integrity, permeability, and activity and composition of the intestinal immune system, on response to ICI has received little attention. Here, we provide an overview of markers to characterize the gut wall and interventions that can modulate these gut wall characteristics. Finally, we present a future perspective on how these gut wall markers and interventions might be utilized and studied to improve ICI treatment strategies. |
|---|---|
| AbstractList | [Display omitted]
•Gut microbiota impacts tumor response to immune checkpoint inhibitors (ICI).•The potential role of the gut wall regarding the tumor response to ICI has received little attention.•Selective markers can define gut wall integrity and the intestinal immune system.•Clinical interventions are available that modify key components of the gut wall.•The gut wall’s potential to improve ICI efficacy should be further explored.
The gut wall is the largest immune organ and forms a barrier through which gut microbiota interact with the immune system in the rest of the body. Gut microbiota composition plays a role in the strength and timing of the anticancer immune response on immune checkpoint inhibitors (ICI). Surprisingly, the effects of gut wall characteristics, such as physical barrier integrity, permeability, and activity and composition of the intestinal immune system, on response to ICI has received little attention. Here, we provide an overview of markers to characterize the gut wall and interventions that can modulate these gut wall characteristics. Finally, we present a future perspective on how these gut wall markers and interventions might be utilized and studied to improve ICI treatment strategies. The gut wall is the largest immune organ and forms a barrier through which gut microbiota interact with the immune system in the rest of the body. Gut microbiota composition plays a role in the strength and timing of the anticancer immune response on immune checkpoint inhibitors (ICI). Surprisingly, the effects of gut wall characteristics, such as physical barrier integrity, permeability, and activity and composition of the intestinal immune system, on response to ICI has received little attention. Here, we provide an overview of markers to characterize the gut wall and interventions that can modulate these gut wall characteristics. Finally, we present a future perspective on how these gut wall markers and interventions might be utilized and studied to improve ICI treatment strategies. |
| ArticleNumber | 102406 |
| Author | de Haan, Jacco J. Fehrmann, Rudolf S.N. Hone Lopez, Sara Nagengast, Wouter B. Jalving, Mathilde de Vries, Elisabeth G.E. |
| Author_xml | – sequence: 1 givenname: Sara surname: Hone Lopez fullname: Hone Lopez, Sara email: s.hone.lopez@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands – sequence: 2 givenname: Mathilde surname: Jalving fullname: Jalving, Mathilde email: m.jalving@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands – sequence: 3 givenname: Rudolf S.N. surname: Fehrmann fullname: Fehrmann, Rudolf S.N. email: r.s.n.fehrmann@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands – sequence: 4 givenname: Wouter B. surname: Nagengast fullname: Nagengast, Wouter B. email: w.b.nagengast@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, the Netherlands – sequence: 5 givenname: Elisabeth G.E. surname: de Vries fullname: de Vries, Elisabeth G.E. email: e.g.e.de.vries@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands – sequence: 6 givenname: Jacco J. surname: de Haan fullname: de Haan, Jacco J. email: j.j.de.haan@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Medical Oncology, Groningen, the Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35569388$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kM1O3DAUha0K1BmGvkAXlZdsMvhn7CQSGzQqFGkkNrBEluPcgKeJHWwHxK6vwevxJPVogCWre3V1ztG53xE6cN4BQj8pWVJC5el2aVJ4WjLCWD6wFZHf0JwKzgpay_IAzQknoih5yWboKMYtIaTmsv6OZlwIWfOqmqO7mwfA91PCz7rv3_69Rjz6BC5Z3WMdscajDslBwJ0PeAxgbLTeYe-M7_39C7YO22GYHGDzAObv6K1LOAXQacgpx-iw032EH-9zgW4vft-s_xSb68ur9fmmMCtCUsFZDTT3XzWMgKmAVlxqTWhbd5VpgQI3XSd01VBuQJdStFI0Vd7bWnPRtHyBTva5Y_CPE8SkBhsN9L124KeomJSCkoqVJEvZXmqCjzFAp8ZgBx1eFCVqh1Vt1Q6r2mFVe6zZ9Os9f2oGaD8tHxyz4GwvgPzlk4WgorHgckObmSXVevtV_n9av41j |
| CitedBy_id | crossref_primary_10_1016_j_celrep_2023_112346 crossref_primary_10_1002_imt2_156 |
| Cites_doi | 10.1016/j.immuni.2017.04.004 10.1007/s00535-018-1480-0 10.1002/1878-0261.13062 10.3390/ijms21239165 10.1038/s41591-022-01695-5 10.3748/wjg.v17.i47.5166 10.1038/nature21349 10.1016/S0016-5085(03)01214-9 10.1111/j.1365-2036.2008.03818.x 10.1016/j.cgh.2018.08.043 10.1097/MIB.0000000000000938 10.1016/S2468-1253(21)00097-2 10.1111/jgh.13242 10.1111/j.1572-0241.2007.01556.x 10.1152/ajpgi.00113.2021 10.1080/19490976.2018.1526583 10.1111/j.1365-2036.2011.04844.x 10.1038/nrgastro.2015.47 10.1186/s12967-020-02231-0 10.1111/j.1365-2036.2009.04194.x 10.14309/ctg.0000000000000320 10.1053/j.gastro.2020.08.005 10.1038/ajg.2015.120 10.1097/00054725-200606000-00003 10.1016/j.cell.2020.06.001 10.1002/ibd.20916 10.14309/ajg.0000000000000827 10.1111/apt.12194 10.1111/j.1572-0241.2006.00672.x 10.3748/wjg.v23.i36.6628 10.5217/ir.2018.16.2.255 10.1007/s11894-019-0740-3 10.1016/j.cgh.2020.05.026 10.1016/j.cgh.2017.12.024 10.1126/science.abb5920 10.1186/s40425-018-0411-1 10.1111/j.1572-0241.2002.07028.x 10.1016/j.cgh.2012.07.006 10.1038/ajg.2013.402 10.1097/MCG.0b013e31819194b0 10.1097/MIB.0000000000000084 10.1097/MCG.0000000000000046 10.1111/apt.13803 10.1126/science.abc3421 10.1016/S1470-2045(18)30952-5 10.1126/science.aaf2834 10.1186/s40425-019-0577-1 10.1007/s00428-021-03170-x 10.1001/jamanetworkopen.2019.2535 10.1038/s41591-022-01702-9 10.1097/MIB.0000000000000166 10.1136/gut.2006.113431 10.1016/j.crohns.2014.08.006 10.1111/j.1365-2036.2011.04805.x 10.1186/s12876-014-0189-7 10.1126/science.aaz7015 10.3748/wjg.v23.i48.8452 10.1186/s40425-019-0658-1 10.1136/gutjnl-2019-318427 10.1177/2050640617737632 10.1097/MPG.0b013e31816bf4bf 10.1001/jamanetworkopen.2020.2895 10.1136/gutjnl-2018-316023 10.1016/j.neo.2017.08.004 10.1093/ecco-jcc/jjaa124 10.1177/2050640619883566 10.1038/s41467-020-16079-x 10.3390/jpm10040208 10.1038/s41575-020-0273-0 10.1093/ecco-jcc/jjab081 10.1097/MIB.0000000000001228 10.1136/gutjnl-2017-315136 10.1258/acb.2009.009061 10.1053/j.gastro.2015.02.008 10.1038/s41591-022-01694-6 10.1111/j.1365-2249.2008.03713.x 10.1158/2159-8290.CD-21-1059 10.1126/science.abf3363 10.1038/mi.2012.75 10.1111/jgh.13598 10.1136/gutjnl-2021-324855 10.1111/jdv.14629 10.1053/j.gastro.2017.05.056 10.1186/s12876-017-0603-z 10.1111/j.1463-1318.2006.00988.x 10.1016/j.crohns.2011.10.004 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: 2022 The Author(s) – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.ctrv.2022.102406 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1967 |
| EndPage | 102406 |
| ExternalDocumentID | 10_1016_j_ctrv_2022_102406 35569388 S0305737222000706 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4CK 4G. 4H- 53G 5GY 5RE 5VS 6I. 6PF 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXUO ABBQC ABJNI ABLJU ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W J5H KOM LCYCR M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WOW WUQ Z5R ZA5 ZGI ~G- AAXKI AKRWK NPM AAYXX AFJKZ CITATION 7X8 |
| ID | FETCH-LOGICAL-c400t-329e12404b20ec8e1836aa01d9f8cde1e3cff5a8b13cea765d65b83ced9a35bd3 |
| IEDL.DBID | AIKHN |
| ISSN | 0305-7372 |
| IngestDate | Fri Oct 25 03:44:34 EDT 2024 Thu Sep 26 18:35:04 EDT 2024 Wed Oct 16 00:41:14 EDT 2024 Fri Feb 23 02:40:43 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Precision Oncology Immune Checkpoint Inhibitors Gut Wall Markers |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c400t-329e12404b20ec8e1836aa01d9f8cde1e3cff5a8b13cea765d65b83ced9a35bd3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0305737222000706 |
| PMID | 35569388 |
| PQID | 2665108270 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_2665108270 crossref_primary_10_1016_j_ctrv_2022_102406 pubmed_primary_35569388 elsevier_sciencedirect_doi_10_1016_j_ctrv_2022_102406 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-01 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Cancer treatment reviews |
| PublicationTitleAlternate | Cancer Treat Rev |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Vieira, Paik, Blaner, Soares, Mota, Guerrant (b0140) 2008; 47 McQuade, Daniel, Helmink, Wargo (b0045) 2019; 20 Leffler, Kelly, Green (b0290) 2015; 148 Bindels, Delzenne, Cani, Walter (b0330) 2015; 12 Jukic, Bakiri, Wagner, Tilg, Adolph (b0145) 2021; 70 Chulkina, Beswick, Pinchuk (b0435) 2020; 21 Camilleri (b0075) 2019; 68 Chang, Leong, Wasinger, Ip, Yang, Phan (b0125) 2017; 153 Celasco, Papa, Jones (b0300) 2010; 31 Straatmijer T, Biemans VBC, Hoentjen F, et al. Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2021;15:1920-1930. doi: 10.1093/ecco-jcc/jjab081. Fritsch, Garces, Quintero, Pignac-Kobinger, Santander, Fernández (b0315) 2021; 19 Zhou, Verne, Fields, Lefante, Basra, Salameh (b0325) 2019; 68 Lee, Thomas, Bolte, Björk, de Ruijter, Armanini (b0385) 2022; 28 Mikhailova, Sishkova, Poniewierka, Zhidkov, Bakulin, Kupcinskas (b0295) 2011; 34 Dizman, Meza, Bergerot, Alcantara, Dorff, Lyou (b0355) 2022; 28 Zeng, Li, Zuo, Zhen, Yang, Liu (b0345) 2008; 28 Van Assche, D'Haens, Noman (b0255) 2003; 125 Derikx, Vreugdenhil, Van den Neucker, Grootjans, van Bijnen, Damoiseaux (b0100) 2009; 43 Bischoff, Barbara, Buurman, Ockhuizen, Schulzke, Serino (b0095) 2014; 14 Hanauer (b0285) 2006 May; 8 Fragkos, Forbes (b0110) 2018; 6 Sakurai, De Velasco, Sakai, Nagai, Nishiyama, Hashimoto (b0375) 2022; 16 Turpin, Lee, Raygoza Garay, Madsen, Meddings, Bedrani (b0085) 2020; 159 Zeissig, Rosati, Dowds, Aden, Bethge, Schulte (b0275) 2019; 68 Pola, Patel, Ramamoorthy, McLemore, Fahmy, Rivera–Nieves (b0250) 2012; 10 Dubois-Camacho, Ottum, Franco-Muñoz, De la Fuente, Torres-Riquelme, Díaz-Jiménez (b0240) 2017; 23 . Frankel, Coughlin, Kim, Froehlich, Xie, Frenkel (b0025) 2017; 19 Vighi, Marcucci, Sensi, Di Cara, Frati (b0050) 2008; 153 Schellekens, Hundscheid, Leenarts, Grootjans, Lenaerts, Buurman (b0115) 2017; 23 Seethaler, Basrai, Neyrinck, Nazare, Walter, Delzenne (b0080) 2021; 321 Mardini, Grigorian (b0350) 2014; 20 Cammarota, Ianiro, Gasbarrini (b0360) 2014; 48 Baruch, Youngster, Ben-Betzalel, Ortenberg, Lahat, Katz (b0040) 2021; 371 Hueso, Gauthier, Joncquel Chevalier-Curt, Magro, Coiteux, Dulery (b0105) 2018; 16 Valcheva, Koleva, Martínez, Walter, Gänzle, Dieleman (b0335) 2019; 10 Haga, Chiba, Shibuya, Osada, Ishikawa, Kodani (b0190) 2016; 31 Palone, Vitali, Cucchiara, Mennini, Armuzzi, Pugliese (b0210) 2016; 22 Perminow, Reikvam, Lyckander, Brandtzaeg, Vatn, Carlsen (b0185) 2009; 15 Blank, Haanen, Ribas, Schumacher (b0020) 2016; 352 Botticelli, Vernocchi, Marini, Quagliariello, Cerbelli, Reddel (b0400) 2020; 18 Smith, Dai, Ghilardi, Amelsberg, Devlin, Pajarillo (b0035) 2022; 28 Adriaanse, Tack, Passos, Damoiseaux, Schreurs, van Wijck (b0090) 2013; 37 Aomatsu, Imaeda, Matsumoto, Kimura, Yoden, Tamai (b0175) 2011; 34 Haslam, Prasad (b0015) 2019; 2 Berman, Parker, Siegel (b0055) 2010; 10 Abu-Sbeih, Ali, Luo, Qiao, Raju, Wang (b0410) 2018; 6 Carroccio, Giannone, Mansueto, Soresi, La Blasca, Fayer (b0180) 2019; 17 D'Haens (b0245) 2016; 44 Salas, Hernandez-Rocha, Duijvestein, Faubion, McGovern, Vermeire (b0220) 2020; 17 Pontes, Vives, Torres, Panés (b0305) 2014; 20 Zizzari, Di Filippo, Scirocchi, Di Pietro, Rahimi, Ugolini (b0390) 2020; 10 Ogata, Yokoyama, Mizushima, Hagino, Hibi (b0280) 2018; 16 Pantavou, Yiallourou, Piovani, Evripidou, Danese, Peyrin-Biroulet (b0225) 2019; 7 Nomura, Nagatomo, Doi, Shimizu, Baba, Saito (b0395) 2020; 3 Nojkov, Zhou, Dolan, Davis, Appelman, Guo (b0120) 2020; 115 Hämäläinen, Sipponen, Kolho (b0230) 2011; 17 Spencer, McQuade, Gopalakrishnan, McCulloch, Vetizou, Cogdill (b0320) 2021; 374 Mosli, Zou, Garg, Feagan, MacDonald, Chande (b0155) 2015; 110 Kaiser, Langhorst, Wittkowski, Becker, Friedrich, Rueffer (b0165) 2007; 56 Langhorst, Elsenbruch, Koelzer, Rueffer, Michalsen, Dobos (b0200) 2008; 103 Narula, Kassam, Yuan, Colombel, Ponsioen, Reinisch (b0365) 2017; 23 Hone Lopez, Kats-Ugurlu, Renken, Buikema, de Groot, Visschedijk (b0425) 2021; 479 Thorsvik, Damås, Granlund, Flo, Bergh, Østvik (b0170) 2017; 32 Chatu, Subramanian, Saxena (b0260) 2014; 109 Barnes, Griseri, Johnson, Young, Powrie, Izcue (b0440) 2013; 6 Chen, Mellman (b0010) 2017; 541 Mager, Burkhard, Pett, Cooke, Brown, Ramay (b0030) 2020; 369 Winterkamp, Weidenhiller, Otte, Stolper, Schwab, Hahn (b0215) 2002; 97 Noth, Stüber, Häsler, Nikolaus, Kühbacher, Hampe (b0235) 2012; 6 Gambichler T, Brown V, Steuke AK, Schmitz L, Stockfleth E, Susok. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J Eur Acad Dermatology Venereol. 2018;32:972–977. doi: 10.1111/jdv.14629. Luoma, Suo, Williams, Sharova, Sullivan, Manos (b0060) 2020; 182 Sasson, Ingram, Zhang, Taylor, Ananthakrishnan, Kaplan (b0310) 2021; 6 Agace, McCoy (b0070) 2017; 46 Pinto-Lopes, Melo, Afonso, Pinto-Lopes, Rocha, Melo (b0205) 2021; 12 Ouaknine Krief, Helly de Tauriers, Dumenil, Neveux, Dumoulin, Giraud (b0065) 2019; 7 Davar, Dzutsev, McCulloch, Rodrigues, Chauvin, Morrison (b0380) 2021; 371 Hanahan (b0005) 2022; 12 Judkins, Archer, Kramer, Solch (b0340) 2020; 22 Holmén, Lundgren, Lundin, Bergin, Rudin, Sjövall (b0195) 2006; 12 Li, Chen, Huo, Wang, Zhang (b0135) 2017; 17 Schreiber, Dignass, Peyrin-Biroulet, Hather, Demuth, Mosli (b0270) 2018; 53 National Library of Medicine (U.S.). (2021, October -). Deep Phenotyping of the Gut Immune System During Immune Checkpoint Inhibitor Therapy – DEFENCE. Identifier NCT04600180. Zollner A, Schmiderer A, Reider SJ, et al. Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2—a comparative study. J Crohn Colitis. 2021;15;43-35. doi: 10.1093/ecco-jcc/jjaa124. Colman, Rubin (b0370) 2014; 8 Coutzac, Jouniaux, Paci, Schmidt, Mallardo, Seck (b0405) 2020; 11 Dunlop, Hebden, Campbell, Naesdal, Olbe, Perkins (b0130) 2006; 101 Joshi, Lewis, Creanor, Ayling (b0160) 2010; 47 Abu-Sbeih, Ali, Wang (b0415) 2019; 2 Turpin (10.1016/j.ctrv.2022.102406_b0085) 2020; 159 Chatu (10.1016/j.ctrv.2022.102406_b0260) 2014; 109 Salas (10.1016/j.ctrv.2022.102406_b0220) 2020; 17 Adriaanse (10.1016/j.ctrv.2022.102406_b0090) 2013; 37 Pontes (10.1016/j.ctrv.2022.102406_b0305) 2014; 20 10.1016/j.ctrv.2022.102406_b0430 Schreiber (10.1016/j.ctrv.2022.102406_b0270) 2018; 53 Zeissig (10.1016/j.ctrv.2022.102406_b0275) 2019; 68 Fritsch (10.1016/j.ctrv.2022.102406_b0315) 2021; 19 Judkins (10.1016/j.ctrv.2022.102406_b0340) 2020; 22 Smith (10.1016/j.ctrv.2022.102406_b0035) 2022; 28 Hueso (10.1016/j.ctrv.2022.102406_b0105) 2018; 16 Kaiser (10.1016/j.ctrv.2022.102406_b0165) 2007; 56 Cammarota (10.1016/j.ctrv.2022.102406_b0360) 2014; 48 Ouaknine Krief (10.1016/j.ctrv.2022.102406_b0065) 2019; 7 Seethaler (10.1016/j.ctrv.2022.102406_b0080) 2021; 321 Pinto-Lopes (10.1016/j.ctrv.2022.102406_b0205) 2021; 12 Chen (10.1016/j.ctrv.2022.102406_b0010) 2017; 541 Thorsvik (10.1016/j.ctrv.2022.102406_b0170) 2017; 32 Vieira (10.1016/j.ctrv.2022.102406_b0140) 2008; 47 Vighi (10.1016/j.ctrv.2022.102406_b0050) 2008; 153 Coutzac (10.1016/j.ctrv.2022.102406_b0405) 2020; 11 Bischoff (10.1016/j.ctrv.2022.102406_b0095) 2014; 14 Mosli (10.1016/j.ctrv.2022.102406_b0155) 2015; 110 Hämäläinen (10.1016/j.ctrv.2022.102406_b0230) 2011; 17 Dubois-Camacho (10.1016/j.ctrv.2022.102406_b0240) 2017; 23 Aomatsu (10.1016/j.ctrv.2022.102406_b0175) 2011; 34 Noth (10.1016/j.ctrv.2022.102406_b0235) 2012; 6 Winterkamp (10.1016/j.ctrv.2022.102406_b0215) 2002; 97 Li (10.1016/j.ctrv.2022.102406_b0135) 2017; 17 Hone Lopez (10.1016/j.ctrv.2022.102406_b0425) 2021; 479 Hanahan (10.1016/j.ctrv.2022.102406_b0005) 2022; 12 Baruch (10.1016/j.ctrv.2022.102406_b0040) 2021; 371 Nojkov (10.1016/j.ctrv.2022.102406_b0120) 2020; 115 Palone (10.1016/j.ctrv.2022.102406_b0210) 2016; 22 Mager (10.1016/j.ctrv.2022.102406_b0030) 2020; 369 Camilleri (10.1016/j.ctrv.2022.102406_b0075) 2019; 68 Spencer (10.1016/j.ctrv.2022.102406_b0320) 2021; 374 Zhou (10.1016/j.ctrv.2022.102406_b0325) 2019; 68 D'Haens (10.1016/j.ctrv.2022.102406_b0245) 2016; 44 Dizman (10.1016/j.ctrv.2022.102406_b0355) 2022; 28 Davar (10.1016/j.ctrv.2022.102406_b0380) 2021; 371 Mardini (10.1016/j.ctrv.2022.102406_b0350) 2014; 20 Pola (10.1016/j.ctrv.2022.102406_b0250) 2012; 10 Pantavou (10.1016/j.ctrv.2022.102406_b0225) 2019; 7 Langhorst (10.1016/j.ctrv.2022.102406_b0200) 2008; 103 Blank (10.1016/j.ctrv.2022.102406_b0020) 2016; 352 Dunlop (10.1016/j.ctrv.2022.102406_b0130) 2006; 101 Joshi (10.1016/j.ctrv.2022.102406_b0160) 2010; 47 Ogata (10.1016/j.ctrv.2022.102406_b0280) 2018; 16 Leffler (10.1016/j.ctrv.2022.102406_b0290) 2015; 148 Hanauer (10.1016/j.ctrv.2022.102406_b0285) 2006; 8 Nomura (10.1016/j.ctrv.2022.102406_b0395) 2020; 3 Luoma (10.1016/j.ctrv.2022.102406_b0060) 2020; 182 Celasco (10.1016/j.ctrv.2022.102406_b0300) 2010; 31 Carroccio (10.1016/j.ctrv.2022.102406_b0180) 2019; 17 Derikx (10.1016/j.ctrv.2022.102406_b0100) 2009; 43 Chang (10.1016/j.ctrv.2022.102406_b0125) 2017; 153 McQuade (10.1016/j.ctrv.2022.102406_b0045) 2019; 20 Zeng (10.1016/j.ctrv.2022.102406_b0345) 2008; 28 Sakurai (10.1016/j.ctrv.2022.102406_b0375) 2022; 16 Abu-Sbeih (10.1016/j.ctrv.2022.102406_b0415) 2019; 2 Chulkina (10.1016/j.ctrv.2022.102406_b0435) 2020; 21 Abu-Sbeih (10.1016/j.ctrv.2022.102406_b0410) 2018; 6 Barnes (10.1016/j.ctrv.2022.102406_b0440) 2013; 6 10.1016/j.ctrv.2022.102406_b0265 Schellekens (10.1016/j.ctrv.2022.102406_b0115) 2017; 23 Narula (10.1016/j.ctrv.2022.102406_b0365) 2017; 23 10.1016/j.ctrv.2022.102406_b0420 Bindels (10.1016/j.ctrv.2022.102406_b0330) 2015; 12 Agace (10.1016/j.ctrv.2022.102406_b0070) 2017; 46 Colman (10.1016/j.ctrv.2022.102406_b0370) 2014; 8 Sasson (10.1016/j.ctrv.2022.102406_b0310) 2021; 6 Botticelli (10.1016/j.ctrv.2022.102406_b0400) 2020; 18 Fragkos (10.1016/j.ctrv.2022.102406_b0110) 2018; 6 Frankel (10.1016/j.ctrv.2022.102406_b0025) 2017; 19 Mikhailova (10.1016/j.ctrv.2022.102406_b0295) 2011; 34 Holmén (10.1016/j.ctrv.2022.102406_b0195) 2006; 12 Lee (10.1016/j.ctrv.2022.102406_b0385) 2022; 28 Berman (10.1016/j.ctrv.2022.102406_b0055) 2010; 10 Haga (10.1016/j.ctrv.2022.102406_b0190) 2016; 31 Jukic (10.1016/j.ctrv.2022.102406_b0145) 2021; 70 10.1016/j.ctrv.2022.102406_b0150 Zizzari (10.1016/j.ctrv.2022.102406_b0390) 2020; 10 Haslam (10.1016/j.ctrv.2022.102406_b0015) 2019; 2 Perminow (10.1016/j.ctrv.2022.102406_b0185) 2009; 15 Van Assche (10.1016/j.ctrv.2022.102406_b0255) 2003; 125 Valcheva (10.1016/j.ctrv.2022.102406_b0335) 2019; 10 |
| References_xml | – volume: 103 start-page: 162 year: 2008 end-page: 169 ident: b0200 article-title: Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices publication-title: Am J Gastroenterol contributor: fullname: Dobos – volume: 3 start-page: e202895 year: 2020 ident: b0395 article-title: Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors publication-title: JAMA Netw Open contributor: fullname: Saito – volume: 101 start-page: 1288 year: 2006 end-page: 1294 ident: b0130 article-title: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes publication-title: Am J Gastroenterol contributor: fullname: Perkins – volume: 541 start-page: 321 year: 2017 end-page: 330 ident: b0010 article-title: Elements of cancer immunity and the cancer–immune set point publication-title: Nature contributor: fullname: Mellman – volume: 125 start-page: 1025 year: 2003 end-page: 1031 ident: b0255 article-title: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis publication-title: Gastroenterology contributor: fullname: Noman – volume: 321 start-page: G11 year: 2021 end-page: G17 ident: b0080 article-title: Biomarkers for assessment of intestinal permeability in clinical practice publication-title: Am J Physiol Gastrointest Liver Physiol contributor: fullname: Delzenne – volume: 17 start-page: 5166 year: 2011 end-page: 5171 ident: b0230 article-title: Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels publication-title: World J Gastroenterol contributor: fullname: Kolho – volume: 7 start-page: 1285 year: 2019 end-page: 1303 ident: b0225 article-title: Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses publication-title: United European Gastroenterol J contributor: fullname: Peyrin-Biroulet – volume: 153 start-page: 723 year: 2017 end-page: 731.e1 ident: b0125 article-title: Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing publication-title: Gastroenterology contributor: fullname: Phan – volume: 44 start-page: 1018 year: 2016 end-page: 1029 ident: b0245 article-title: Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis publication-title: Aliment Pharmacol Ther contributor: fullname: D'Haens – volume: 47 start-page: 259 year: 2010 end-page: 263 ident: b0160 article-title: Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers publication-title: Ann Clin Biochem contributor: fullname: Ayling – volume: 6 start-page: 464 year: 2012 end-page: 469 ident: b0235 article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn’s disease publication-title: J Crohns Colitis contributor: fullname: Hampe – volume: 10 start-page: 1315 year: 2012 end-page: 1325.e4 ident: b0250 article-title: Strategies for the care of adults hospitalized for active ulcerative colitis publication-title: Clin Gastroenterol Hepatol contributor: fullname: Rivera–Nieves – volume: 68 start-page: 1516 year: 2019 end-page: 1526 ident: b0075 article-title: Leaky gut: mechanisms, measurement and clinical implications in humans publication-title: Gut contributor: fullname: Camilleri – volume: 16 start-page: 908 year: 2018 end-page: 917.e2 ident: b0105 article-title: Association between low plasma level of citrulline before allogeneic hematopoietic cell transplantation and severe gastrointestinal graft vs host disease publication-title: Clin Gastroenterol Hepatol contributor: fullname: Dulery – volume: 46 start-page: 532 year: 2017 end-page: 548 ident: b0070 article-title: Regionalized development and maintenance of the intestinal adaptive immune landscape publication-title: Immunity contributor: fullname: McCoy – volume: 28 start-page: 704 year: 2022 end-page: 712 ident: b0355 article-title: Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial publication-title: Nature Med contributor: fullname: Lyou – volume: 11 year: 2020 ident: b0405 article-title: Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer publication-title: Nat Comm contributor: fullname: Seck – volume: 47 start-page: 652 year: 2008 end-page: 659 ident: b0140 article-title: Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil publication-title: J Pediatr Gastroenterol Nutr contributor: fullname: Guerrant – volume: 43 start-page: 727 year: 2009 end-page: 733 ident: b0100 article-title: A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP publication-title: J Clin Gastroenterol contributor: fullname: Damoiseaux – volume: 34 start-page: 941 year: 2011 end-page: 948 ident: b0175 article-title: Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease publication-title: Aliment Pharmacol Ther contributor: fullname: Tamai – volume: 12 start-page: 31 year: 2022 end-page: 46 ident: b0005 article-title: Hallmarks of cancer: new dimensions publication-title: Cancer Discov contributor: fullname: Hanahan – volume: 10 start-page: 11 year: 2010 ident: b0055 article-title: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma publication-title: Cancer Immun contributor: fullname: Siegel – volume: 7 year: 2019 ident: b0065 article-title: Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab publication-title: J Immunother Cancer contributor: fullname: Giraud – volume: 16 start-page: 1493 year: 2022 end-page: 1507 ident: b0375 article-title: Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis publication-title: Mol Oncol contributor: fullname: Hashimoto – volume: 10 start-page: 208 year: 2020 ident: b0390 article-title: Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients publication-title: J Pers Med contributor: fullname: Ugolini – volume: 20 start-page: e77 year: 2019 end-page: e91 ident: b0045 article-title: Modulating the microbiome to improve therapeutic response in cancer publication-title: Lancet Oncol contributor: fullname: Wargo – volume: 153 start-page: 3 year: 2008 end-page: 6 ident: b0050 article-title: Allergy and the gastrointestinal system publication-title: Clin Exp Immunol contributor: fullname: Frati – volume: 110 start-page: 802 year: 2015 end-page: 819 ident: b0155 article-title: C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis publication-title: Am J Gastroenterol contributor: fullname: Chande – volume: 17 start-page: 682 year: 2019 end-page: 690.e3 ident: b0180 article-title: Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity publication-title: Clin Gastroenterol Hepatol contributor: fullname: Fayer – volume: 8 start-page: 20 year: 2006 May end-page: 24 ident: b0285 article-title: New lessons: classic treatments, expanding options in ulcerative colitis publication-title: Colorectal Dis contributor: fullname: Hanauer – volume: 37 start-page: 482 year: 2013 end-page: 490 ident: b0090 article-title: Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies publication-title: Aliment Pharmacol Ther contributor: fullname: van Wijck – volume: 32 start-page: 128 year: 2017 end-page: 135 ident: b0170 article-title: Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease publication-title: J Gastroenterol Hepatol contributor: fullname: Østvik – volume: 12 start-page: 447 year: 2006 end-page: 456 ident: b0195 article-title: Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity publication-title: Inflamm Bowel Dis contributor: fullname: Sjövall – volume: 31 start-page: 375 year: 2010 end-page: 386 ident: b0300 article-title: Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis publication-title: Aliment Pharmacol Ther contributor: fullname: Jones – volume: 2 start-page: 93 year: 2019 ident: b0415 article-title: Early introduction of selective immunosuppressive therapy associated with favourable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis publication-title: J Immunother Cancer contributor: fullname: Wang – volume: 17 start-page: 323 year: 2020 end-page: 337 ident: b0220 article-title: JAK-STAT pathway targeting for the treatment of inflammatory bowel disease publication-title: Nat Rev Gastroenterol Hepatol contributor: fullname: Vermeire – volume: 23 start-page: 8452 year: 2017 end-page: 8464 ident: b0115 article-title: Human small intestine is capable of restoring barrier function after short ischemic periods publication-title: World J Gastroenterol contributor: fullname: Buurman – volume: 371 start-page: 595 year: 2021 end-page: 602 ident: b0380 article-title: Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients publication-title: Science contributor: fullname: Morrison – volume: 6 start-page: 324 year: 2013 end-page: 334 ident: b0440 article-title: CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria publication-title: Mucosal Immunol contributor: fullname: Izcue – volume: 20 start-page: 2004 year: 2014 end-page: 2012 ident: b0305 article-title: Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomised proof of concept study publication-title: Inflamm Bowel Dis contributor: fullname: Panés – volume: 22 start-page: 2886 year: 2016 end-page: 2893 ident: b0210 article-title: Fecal HMGB1 Reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission publication-title: Inflamm Bowel Dis contributor: fullname: Pugliese – volume: 28 start-page: 535 year: 2022 end-page: 544 ident: b0385 article-title: Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma publication-title: Nat Med contributor: fullname: Armanini – volume: 14 year: 2014 ident: b0095 article-title: Intestinal permeability–a new target for disease prevention and therapy publication-title: BMC Gastroenterol contributor: fullname: Serino – volume: 369 start-page: 1481 year: 2020 end-page: 1489 ident: b0030 article-title: Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy publication-title: Science contributor: fullname: Ramay – volume: 148 start-page: 1311 year: 2015 end-page: 1319 ident: b0290 article-title: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomised controlled trial publication-title: Gastroenterology contributor: fullname: Green – volume: 56 start-page: 1706 year: 2007 end-page: 1713 ident: b0165 article-title: Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome publication-title: Gut contributor: fullname: Rueffer – volume: 2 start-page: e192535 year: 2019 ident: b0015 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open contributor: fullname: Prasad – volume: 23 start-page: 6628 year: 2017 end-page: 6638 ident: b0240 article-title: Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology publication-title: World J Gastroenterol contributor: fullname: Díaz-Jiménez – volume: 12 start-page: e00320 year: 2021 ident: b0205 article-title: Fecal Dipeptidyl Peptidase-4: An emergent biomarker in inflammatory bowel disease publication-title: Clin Transl Gastroenterol contributor: fullname: Melo – volume: 6 start-page: 754 year: 2021 end-page: 769 ident: b0310 article-title: The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease publication-title: Lancet Gastroenterol Hepatol contributor: fullname: Kaplan – volume: 18 year: 2020 ident: b0400 article-title: Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment publication-title: J Transl Med contributor: fullname: Reddel – volume: 20 start-page: 1562 year: 2014 end-page: 1567 ident: b0350 article-title: Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis publication-title: Inflamm Bowel Dis contributor: fullname: Grigorian – volume: 15 start-page: 1368 year: 2009 end-page: 1378 ident: b0185 article-title: Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn's disease publication-title: Inflamm Bowel Dis contributor: fullname: Carlsen – volume: 374 start-page: 1632 year: 2021 end-page: 1640 ident: b0320 article-title: Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response publication-title: Science contributor: fullname: Cogdill – volume: 6 start-page: 95 year: 2018 ident: b0410 article-title: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis publication-title: J Immunother Cancer contributor: fullname: Wang – volume: 10 start-page: 334 year: 2019 end-page: 357 ident: b0335 article-title: Inulin- type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels publication-title: Gut Microbes contributor: fullname: Dieleman – volume: 479 start-page: 1119 year: 2021 end-page: 1129 ident: b0425 article-title: Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis publication-title: Virchows Arch contributor: fullname: Visschedijk – volume: 182 start-page: 655 year: 2020 end-page: 671.e22 ident: b0060 article-title: Molecular pathways of colon inflammation induced by cancer immunotherapy publication-title: Cell contributor: fullname: Manos – volume: 19 start-page: 1189 year: 2021 end-page: 1199.e30 ident: b0315 article-title: Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis publication-title: Clin Gastroenterol Hepatol contributor: fullname: Fernández – volume: 19 start-page: 848 year: 2017 end-page: 855 ident: b0025 article-title: Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients publication-title: Neoplasia contributor: fullname: Frenkel – volume: 8 start-page: 1569 year: 2014 end-page: 1581 ident: b0370 article-title: Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis publication-title: J Crohns Colitis contributor: fullname: Rubin – volume: 17 start-page: 45 year: 2017 ident: b0135 article-title: Association between acute gastrointestinal injury and biomarkers of intestinal barrier function in critically ill patients publication-title: BMC Gastroenterol contributor: fullname: Zhang – volume: 22 start-page: 2 year: 2020 ident: b0340 article-title: Probiotics, nutrition, and the small intestine publication-title: Curr Gastroenterol Rep contributor: fullname: Solch – volume: 34 start-page: 1088 year: 2011 end-page: 1097 ident: b0295 article-title: Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment publication-title: Aliment Pharmacol Ther contributor: fullname: Kupcinskas – volume: 28 start-page: 994 year: 2008 end-page: 1002 ident: b0345 article-title: Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome publication-title: Aliment Pharmacol Ther contributor: fullname: Liu – volume: 68 start-page: 996 year: 2019 end-page: 1002 ident: b0325 article-title: Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome publication-title: Gut contributor: fullname: Salameh – volume: 159 start-page: 2092 year: 2020 end-page: 2100.e5 ident: b0085 article-title: Increased intestinal permeability is associated with later development of Crohn’s disease publication-title: Gastroenterology contributor: fullname: Bedrani – volume: 21 start-page: 9165 year: 2020 ident: b0435 article-title: Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation publication-title: Int J Mol Sci contributor: fullname: Pinchuk – volume: 12 start-page: 303 year: 2015 end-page: 310 ident: b0330 article-title: Towards a more comprehensive concept for prebiotics publication-title: Nat Rev Gastroenterol Hepatol contributor: fullname: Walter – volume: 23 start-page: 1702 year: 2017 end-page: 1709 ident: b0365 article-title: Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis publication-title: Inflamm Bowel Dis contributor: fullname: Reinisch – volume: 109 start-page: 23 year: 2014 end-page: 34 ident: b0260 article-title: The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis publication-title: Am J Gastroenterol contributor: fullname: Saxena – volume: 31 start-page: 965 year: 2016 end-page: 972 ident: b0190 article-title: MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis publication-title: J Gastroenterol Hepatol contributor: fullname: Kodani – volume: 371 start-page: 602 year: 2021 end-page: 609 ident: b0040 article-title: Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients publication-title: Science contributor: fullname: Katz – volume: 70 start-page: 1978 year: 2021 end-page: 1988 ident: b0145 article-title: Calprotectin: from biomarker to biological function publication-title: Gut contributor: fullname: Adolph – volume: 16 start-page: 255 year: 2018 ident: b0280 article-title: Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study publication-title: Intest Res contributor: fullname: Hibi – volume: 28 start-page: 713 year: 2022 end-page: 723 ident: b0035 article-title: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy publication-title: Nat Med contributor: fullname: Pajarillo – volume: 97 start-page: 3071 year: 2002 end-page: 3077 ident: b0215 article-title: Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease publication-title: Am J Gastroenterol contributor: fullname: Hahn – volume: 6 start-page: 181 year: 2018 end-page: 191 ident: b0110 article-title: Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis publication-title: United European Gastroenterol J contributor: fullname: Forbes – volume: 53 start-page: 1048 year: 2018 end-page: 1064 ident: b0270 article-title: Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease publication-title: J Gastroenterol contributor: fullname: Mosli – volume: 115 start-page: 1891 year: 2020 end-page: 1901 ident: b0120 article-title: Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and “ex vivo” mucosa analysis publication-title: Am J Gastroenterol contributor: fullname: Guo – volume: 48 start-page: 693 year: 2014 end-page: 702 ident: b0360 article-title: Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review publication-title: J Clin Gastroenterol contributor: fullname: Gasbarrini – volume: 352 start-page: 658 year: 2016 end-page: 660 ident: b0020 article-title: Cancer immunology. The “cancer immunogram” publication-title: Science contributor: fullname: Schumacher – volume: 68 start-page: 25 year: 2019 end-page: 39 ident: b0275 article-title: Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease publication-title: Gut contributor: fullname: Schulte – volume: 46 start-page: 532 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0070 article-title: Regionalized development and maintenance of the intestinal adaptive immune landscape publication-title: Immunity doi: 10.1016/j.immuni.2017.04.004 contributor: fullname: Agace – volume: 53 start-page: 1048 issue: 9 year: 2018 ident: 10.1016/j.ctrv.2022.102406_b0270 article-title: Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease publication-title: J Gastroenterol doi: 10.1007/s00535-018-1480-0 contributor: fullname: Schreiber – volume: 16 start-page: 1493 issue: 7 year: 2022 ident: 10.1016/j.ctrv.2022.102406_b0375 article-title: Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis publication-title: Mol Oncol doi: 10.1002/1878-0261.13062 contributor: fullname: Sakurai – volume: 21 start-page: 9165 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0435 article-title: Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation publication-title: Int J Mol Sci doi: 10.3390/ijms21239165 contributor: fullname: Chulkina – volume: 28 start-page: 535 issue: 3 year: 2022 ident: 10.1016/j.ctrv.2022.102406_b0385 article-title: Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma publication-title: Nat Med doi: 10.1038/s41591-022-01695-5 contributor: fullname: Lee – volume: 17 start-page: 5166 year: 2011 ident: 10.1016/j.ctrv.2022.102406_b0230 article-title: Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels publication-title: World J Gastroenterol doi: 10.3748/wjg.v17.i47.5166 contributor: fullname: Hämäläinen – volume: 541 start-page: 321 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0010 article-title: Elements of cancer immunity and the cancer–immune set point publication-title: Nature doi: 10.1038/nature21349 contributor: fullname: Chen – volume: 125 start-page: 1025 year: 2003 ident: 10.1016/j.ctrv.2022.102406_b0255 article-title: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis publication-title: Gastroenterology doi: 10.1016/S0016-5085(03)01214-9 contributor: fullname: Van Assche – volume: 28 start-page: 994 year: 2008 ident: 10.1016/j.ctrv.2022.102406_b0345 article-title: Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03818.x contributor: fullname: Zeng – volume: 17 start-page: 682 issue: 4 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0180 article-title: Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.08.043 contributor: fullname: Carroccio – volume: 22 start-page: 2886 issue: 12 year: 2016 ident: 10.1016/j.ctrv.2022.102406_b0210 article-title: Fecal HMGB1 Reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000938 contributor: fullname: Palone – volume: 6 start-page: 754 issue: 9 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0310 article-title: The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(21)00097-2 contributor: fullname: Sasson – volume: 31 start-page: 965 issue: 5 year: 2016 ident: 10.1016/j.ctrv.2022.102406_b0190 article-title: MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13242 contributor: fullname: Haga – volume: 103 start-page: 162 year: 2008 ident: 10.1016/j.ctrv.2022.102406_b0200 article-title: Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2007.01556.x contributor: fullname: Langhorst – volume: 321 start-page: G11 issue: 1 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0080 article-title: Biomarkers for assessment of intestinal permeability in clinical practice publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00113.2021 contributor: fullname: Seethaler – volume: 10 start-page: 334 issue: 3 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0335 article-title: Inulin- type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels publication-title: Gut Microbes doi: 10.1080/19490976.2018.1526583 contributor: fullname: Valcheva – volume: 34 start-page: 1088 issue: 9 year: 2011 ident: 10.1016/j.ctrv.2022.102406_b0295 article-title: Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04844.x contributor: fullname: Mikhailova – volume: 12 start-page: 303 issue: 5 year: 2015 ident: 10.1016/j.ctrv.2022.102406_b0330 article-title: Towards a more comprehensive concept for prebiotics publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2015.47 contributor: fullname: Bindels – volume: 18 issue: 1 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0400 article-title: Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment publication-title: J Transl Med doi: 10.1186/s12967-020-02231-0 contributor: fullname: Botticelli – volume: 31 start-page: 375 year: 2010 ident: 10.1016/j.ctrv.2022.102406_b0300 article-title: Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2009.04194.x contributor: fullname: Celasco – volume: 12 start-page: e00320 issue: 3 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0205 article-title: Fecal Dipeptidyl Peptidase-4: An emergent biomarker in inflammatory bowel disease publication-title: Clin Transl Gastroenterol doi: 10.14309/ctg.0000000000000320 contributor: fullname: Pinto-Lopes – volume: 159 start-page: 2092 issue: 6 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0085 article-title: Increased intestinal permeability is associated with later development of Crohn’s disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.08.005 contributor: fullname: Turpin – volume: 110 start-page: 802 issue: 6 year: 2015 ident: 10.1016/j.ctrv.2022.102406_b0155 article-title: C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2015.120 contributor: fullname: Mosli – volume: 12 start-page: 447 issue: 6 year: 2006 ident: 10.1016/j.ctrv.2022.102406_b0195 article-title: Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity publication-title: Inflamm Bowel Dis doi: 10.1097/00054725-200606000-00003 contributor: fullname: Holmén – volume: 182 start-page: 655 issue: 3 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0060 article-title: Molecular pathways of colon inflammation induced by cancer immunotherapy publication-title: Cell doi: 10.1016/j.cell.2020.06.001 contributor: fullname: Luoma – volume: 15 start-page: 1368 year: 2009 ident: 10.1016/j.ctrv.2022.102406_b0185 article-title: Increased number and activation of colonic macrophages in pediatric patients with untreated Crohn's disease publication-title: Inflamm Bowel Dis doi: 10.1002/ibd.20916 contributor: fullname: Perminow – volume: 115 start-page: 1891 issue: 11 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0120 article-title: Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and “ex vivo” mucosa analysis publication-title: Am J Gastroenterol doi: 10.14309/ajg.0000000000000827 contributor: fullname: Nojkov – volume: 37 start-page: 482 issue: 4 year: 2013 ident: 10.1016/j.ctrv.2022.102406_b0090 article-title: Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12194 contributor: fullname: Adriaanse – volume: 101 start-page: 1288 issue: 6 year: 2006 ident: 10.1016/j.ctrv.2022.102406_b0130 article-title: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2006.00672.x contributor: fullname: Dunlop – volume: 23 start-page: 6628 issue: 36 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0240 article-title: Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology publication-title: World J Gastroenterol doi: 10.3748/wjg.v23.i36.6628 contributor: fullname: Dubois-Camacho – volume: 16 start-page: 255 issue: 2 year: 2018 ident: 10.1016/j.ctrv.2022.102406_b0280 article-title: Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study publication-title: Intest Res doi: 10.5217/ir.2018.16.2.255 contributor: fullname: Ogata – volume: 22 start-page: 2 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0340 article-title: Probiotics, nutrition, and the small intestine publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-019-0740-3 contributor: fullname: Judkins – volume: 19 start-page: 1189 issue: 6 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0315 article-title: Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2020.05.026 contributor: fullname: Fritsch – volume: 16 start-page: 908 issue: 6 year: 2018 ident: 10.1016/j.ctrv.2022.102406_b0105 article-title: Association between low plasma level of citrulline before allogeneic hematopoietic cell transplantation and severe gastrointestinal graft vs host disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.12.024 contributor: fullname: Hueso – volume: 371 start-page: 602 issue: 6529 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0040 article-title: Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients publication-title: Science doi: 10.1126/science.abb5920 contributor: fullname: Baruch – volume: 6 start-page: 95 year: 2018 ident: 10.1016/j.ctrv.2022.102406_b0410 article-title: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0411-1 contributor: fullname: Abu-Sbeih – volume: 97 start-page: 3071 issue: 12 year: 2002 ident: 10.1016/j.ctrv.2022.102406_b0215 article-title: Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.07028.x contributor: fullname: Winterkamp – volume: 10 start-page: 1315 issue: 12 year: 2012 ident: 10.1016/j.ctrv.2022.102406_b0250 article-title: Strategies for the care of adults hospitalized for active ulcerative colitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2012.07.006 contributor: fullname: Pola – volume: 109 start-page: 23 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0260 article-title: The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis publication-title: Am J Gastroenterol doi: 10.1038/ajg.2013.402 contributor: fullname: Chatu – volume: 43 start-page: 727 issue: 8 year: 2009 ident: 10.1016/j.ctrv.2022.102406_b0100 article-title: A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0b013e31819194b0 contributor: fullname: Derikx – volume: 20 start-page: 1562 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0350 article-title: Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000084 contributor: fullname: Mardini – volume: 48 start-page: 693 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0360 article-title: Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review publication-title: J Clin Gastroenterol doi: 10.1097/MCG.0000000000000046 contributor: fullname: Cammarota – volume: 44 start-page: 1018 year: 2016 ident: 10.1016/j.ctrv.2022.102406_b0245 article-title: Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13803 contributor: fullname: D'Haens – volume: 369 start-page: 1481 issue: 6510 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0030 article-title: Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy publication-title: Science doi: 10.1126/science.abc3421 contributor: fullname: Mager – volume: 20 start-page: e77 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0045 article-title: Modulating the microbiome to improve therapeutic response in cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30952-5 contributor: fullname: McQuade – volume: 352 start-page: 658 year: 2016 ident: 10.1016/j.ctrv.2022.102406_b0020 article-title: Cancer immunology. The “cancer immunogram” publication-title: Science doi: 10.1126/science.aaf2834 contributor: fullname: Blank – volume: 2 start-page: 93 issue: 7 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0415 article-title: Early introduction of selective immunosuppressive therapy associated with favourable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0577-1 contributor: fullname: Abu-Sbeih – volume: 479 start-page: 1119 issue: 6 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0425 article-title: Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis publication-title: Virchows Arch doi: 10.1007/s00428-021-03170-x contributor: fullname: Hone Lopez – ident: 10.1016/j.ctrv.2022.102406_b0430 – volume: 2 start-page: e192535 issue: 5 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0015 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 contributor: fullname: Haslam – volume: 28 start-page: 713 issue: 4 year: 2022 ident: 10.1016/j.ctrv.2022.102406_b0035 article-title: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy publication-title: Nat Med doi: 10.1038/s41591-022-01702-9 contributor: fullname: Smith – volume: 20 start-page: 2004 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0305 article-title: Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomised proof of concept study publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000166 contributor: fullname: Pontes – volume: 56 start-page: 1706 issue: 12 year: 2007 ident: 10.1016/j.ctrv.2022.102406_b0165 article-title: Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome publication-title: Gut doi: 10.1136/gut.2006.113431 contributor: fullname: Kaiser – volume: 8 start-page: 1569 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0370 article-title: Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2014.08.006 contributor: fullname: Colman – volume: 34 start-page: 941 issue: 8 year: 2011 ident: 10.1016/j.ctrv.2022.102406_b0175 article-title: Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2011.04805.x contributor: fullname: Aomatsu – volume: 14 issue: 1 year: 2014 ident: 10.1016/j.ctrv.2022.102406_b0095 article-title: Intestinal permeability–a new target for disease prevention and therapy publication-title: BMC Gastroenterol doi: 10.1186/s12876-014-0189-7 contributor: fullname: Bischoff – volume: 374 start-page: 1632 issue: 6575 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0320 article-title: Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response publication-title: Science doi: 10.1126/science.aaz7015 contributor: fullname: Spencer – volume: 23 start-page: 8452 issue: 48 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0115 article-title: Human small intestine is capable of restoring barrier function after short ischemic periods publication-title: World J Gastroenterol doi: 10.3748/wjg.v23.i48.8452 contributor: fullname: Schellekens – volume: 7 issue: 1 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0065 article-title: Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0658-1 contributor: fullname: Ouaknine Krief – volume: 68 start-page: 1516 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0075 article-title: Leaky gut: mechanisms, measurement and clinical implications in humans publication-title: Gut doi: 10.1136/gutjnl-2019-318427 contributor: fullname: Camilleri – volume: 6 start-page: 181 year: 2018 ident: 10.1016/j.ctrv.2022.102406_b0110 article-title: Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis publication-title: United European Gastroenterol J doi: 10.1177/2050640617737632 contributor: fullname: Fragkos – volume: 47 start-page: 652 issue: 5 year: 2008 ident: 10.1016/j.ctrv.2022.102406_b0140 article-title: Carotenoids, retinol, and intestinal barrier function in children from northeastern Brazil publication-title: J Pediatr Gastroenterol Nutr doi: 10.1097/MPG.0b013e31816bf4bf contributor: fullname: Vieira – volume: 3 start-page: e202895 issue: 4 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0395 article-title: Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.2895 contributor: fullname: Nomura – volume: 68 start-page: 25 issue: 1 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0275 article-title: Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease publication-title: Gut doi: 10.1136/gutjnl-2018-316023 contributor: fullname: Zeissig – volume: 19 start-page: 848 issue: 10 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0025 article-title: Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients publication-title: Neoplasia doi: 10.1016/j.neo.2017.08.004 contributor: fullname: Frankel – ident: 10.1016/j.ctrv.2022.102406_b0150 doi: 10.1093/ecco-jcc/jjaa124 – volume: 7 start-page: 1285 issue: 10 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0225 article-title: Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses publication-title: United European Gastroenterol J doi: 10.1177/2050640619883566 contributor: fullname: Pantavou – volume: 11 issue: 1 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0405 article-title: Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer publication-title: Nat Comm doi: 10.1038/s41467-020-16079-x contributor: fullname: Coutzac – volume: 10 start-page: 208 issue: 4 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0390 article-title: Soluble immune checkpoints, gut metabolites and performance status as parameters of response to nivolumab treatment in NSCLC patients publication-title: J Pers Med doi: 10.3390/jpm10040208 contributor: fullname: Zizzari – volume: 17 start-page: 323 issue: 6 year: 2020 ident: 10.1016/j.ctrv.2022.102406_b0220 article-title: JAK-STAT pathway targeting for the treatment of inflammatory bowel disease publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-020-0273-0 contributor: fullname: Salas – ident: 10.1016/j.ctrv.2022.102406_b0265 doi: 10.1093/ecco-jcc/jjab081 – volume: 23 start-page: 1702 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0365 article-title: Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000001228 contributor: fullname: Narula – volume: 68 start-page: 996 issue: 6 year: 2019 ident: 10.1016/j.ctrv.2022.102406_b0325 article-title: Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome publication-title: Gut doi: 10.1136/gutjnl-2017-315136 contributor: fullname: Zhou – volume: 10 start-page: 11 year: 2010 ident: 10.1016/j.ctrv.2022.102406_b0055 article-title: Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma publication-title: Cancer Immun contributor: fullname: Berman – volume: 47 start-page: 259 year: 2010 ident: 10.1016/j.ctrv.2022.102406_b0160 article-title: Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers publication-title: Ann Clin Biochem doi: 10.1258/acb.2009.009061 contributor: fullname: Joshi – volume: 148 start-page: 1311 year: 2015 ident: 10.1016/j.ctrv.2022.102406_b0290 article-title: Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomised controlled trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.02.008 contributor: fullname: Leffler – volume: 28 start-page: 704 issue: 4 year: 2022 ident: 10.1016/j.ctrv.2022.102406_b0355 article-title: Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial publication-title: Nature Med doi: 10.1038/s41591-022-01694-6 contributor: fullname: Dizman – volume: 153 start-page: 3 issue: Suppl 1 year: 2008 ident: 10.1016/j.ctrv.2022.102406_b0050 article-title: Allergy and the gastrointestinal system publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2008.03713.x contributor: fullname: Vighi – volume: 12 start-page: 31 year: 2022 ident: 10.1016/j.ctrv.2022.102406_b0005 article-title: Hallmarks of cancer: new dimensions publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-21-1059 contributor: fullname: Hanahan – volume: 371 start-page: 595 issue: 6529 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0380 article-title: Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients publication-title: Science doi: 10.1126/science.abf3363 contributor: fullname: Davar – volume: 6 start-page: 324 year: 2013 ident: 10.1016/j.ctrv.2022.102406_b0440 article-title: CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria publication-title: Mucosal Immunol doi: 10.1038/mi.2012.75 contributor: fullname: Barnes – volume: 32 start-page: 128 issue: 1 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0170 article-title: Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.13598 contributor: fullname: Thorsvik – volume: 70 start-page: 1978 year: 2021 ident: 10.1016/j.ctrv.2022.102406_b0145 article-title: Calprotectin: from biomarker to biological function publication-title: Gut doi: 10.1136/gutjnl-2021-324855 contributor: fullname: Jukic – ident: 10.1016/j.ctrv.2022.102406_b0420 doi: 10.1111/jdv.14629 – volume: 153 start-page: 723 issue: 3 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0125 article-title: Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.05.056 contributor: fullname: Chang – volume: 17 start-page: 45 year: 2017 ident: 10.1016/j.ctrv.2022.102406_b0135 article-title: Association between acute gastrointestinal injury and biomarkers of intestinal barrier function in critically ill patients publication-title: BMC Gastroenterol doi: 10.1186/s12876-017-0603-z contributor: fullname: Li – volume: 8 start-page: 20 issue: Suppl 1 year: 2006 ident: 10.1016/j.ctrv.2022.102406_b0285 article-title: New lessons: classic treatments, expanding options in ulcerative colitis publication-title: Colorectal Dis doi: 10.1111/j.1463-1318.2006.00988.x contributor: fullname: Hanauer – volume: 6 start-page: 464 issue: 4 year: 2012 ident: 10.1016/j.ctrv.2022.102406_b0235 article-title: Anti-TNF-α antibodies improve intestinal barrier function in Crohn’s disease publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2011.10.004 contributor: fullname: Noth |
| SSID | ssj0009369 |
| Score | 2.4256806 |
| SecondaryResourceType | review_article |
| Snippet | [Display omitted]
•Gut microbiota impacts tumor response to immune checkpoint inhibitors (ICI).•The potential role of the gut wall regarding the tumor response... The gut wall is the largest immune organ and forms a barrier through which gut microbiota interact with the immune system in the rest of the body. Gut... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 102406 |
| SubjectTerms | Gut Wall Immune Checkpoint Inhibitors Markers Precision Oncology |
| Title | The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment |
| URI | https://dx.doi.org/10.1016/j.ctrv.2022.102406 https://www.ncbi.nlm.nih.gov/pubmed/35569388 https://search.proquest.com/docview/2665108270 |
| Volume | 107 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VrYS4IGh5bGkrI_WGwiZx4iTHqmq1sGoPQEUvyPIrVaBKot1sERfE3-Dv8Us6kzhFSNADpzyUUewZe_yN5gVwwAV3VvAyEIktgiSxOlBZkQc6NCpTqQ61oUTh0zMxP0_eXqQXG3A05sJQWKXX_YNO77W1fzPz3Jy1VTV7T0uVmqzElG2SUdntzd5JNIHNwzeL-dnv2ru872xH3wdE4HNnhjAv0y2v0UyMYypikFDjo7-fT__Cn_05dPIIHnoAyQ6HMT6GDVdvwf1T7yLfhk8oeHa57thXdXX168fPFWubjkKCkEitmGItTq92S4ZolbVL32KHNXVfvvobq2pWUc6IYyhO86Vtqrpjt-HoT-D85PjD0TzwPRQCg7uzC3hcODzCw0THoTO5wx0slAojW5S5sS5y3JRlqnIdceNUJlIrUp3jvS0UT7XlT2FSN7V7DkxZNJWiTFPhgoTHXCN4yHhiSzS6rI3EFF6NnJPtUCpDjjFknyXxWRKf5cDnKaQjc-UfApeoy--kezlKQuJOIPeGql2zXkmEGqhg8jgLp_BsENHtOBBViYLn-c5__vUFPKCnIUZsFybdcu32EI10eh_uvf4e7fs1R9fFu4-LG0MW4PA |
| link.rule.ids | 315,783,787,4511,24130,27938,27939,45599,45693 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS-RAEG7EBd2LrK91XFd7wZvESdKdTnIUWRldx4sKXqTpVyQqSZjJKF6W_Rv79_wlVk0SRVAP3kKSJp169df0V1WEbDPBnBUs8wS3qce51Z6K08TTvlGxirSvDSYKD0_E4JwfXUQXM2S_y4VBWmUb-5uYPo3W7Z1-K81-lef9UzRVbLISYrZJjGW3v3CsnwVGvfv3heeBHeuao4TIw9fbzJmG5GXq0R1sEsMQSxhwbHv09ur0HvqcrkIH38hCCx_pXjPDRTLjiiUyN2wPyJfJJaidXk1qeq9ubx___R_TqqyREASD1JgqWsHPFW5EAavSatQ22KFlMS1e_UDzguaYMeIoKNPcVGVe1PSZjL5Czg9-n-0PvLaDgmfAN2uPhamDBdznOvSdSRz4r1DKD2yaJca6wDGTZZFKdMCMU7GIrIh0Atc2VSzSlq2S2aIs3BqhysJGKYg1li3gLGQaoEPMuM1gy2VtIHpkp5OcrJpCGbJjkF1LlLNEOctGzj0SdcKVr9QtIZJ_OO5XpwkJfoCHG6pw5WQsAWhAeEnC2O-R742KnucBmEqkLEnWP_nVLTI_OBsey-PDkz8_yFd80rDFNshsPZq4n4BLar05tbsnXU3gLw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+gut+wall%27s+potential+as+a+partner+for+precision+oncology+in+immune+checkpoint+treatment&rft.jtitle=Cancer+treatment+reviews&rft.au=Hone+Lopez%2C+Sara&rft.au=Jalving%2C+Mathilde&rft.au=Fehrmann%2C+Rudolf+S+N&rft.au=Nagengast%2C+Wouter+B&rft.date=2022-06-01&rft.eissn=1532-1967&rft.volume=107&rft.spage=102406&rft.epage=102406&rft_id=info:doi/10.1016%2Fj.ctrv.2022.102406&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7372&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7372&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7372&client=summon |